ZAZZI MAURIZIO | Elenco docenti

Marchi, S., Dragoni, F., Boccuto, A., Idoko, O.T., Zazzi, M., Sow, S., et al. (2023). Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage. ACTA TROPICA, 237, 1-5 [10.1016/j.actatropica.2022.106736]. - dettaglio
Vicenti, I., Basso, M., Pirola, N., Bragato, B., Rossi, M.C., Giobbia, M., et al. (2023). SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy. VACCINES, 11(4), 871 [10.3390/vaccines11040871]. - dettaglio
Salvo, P.F., Farinacci, D., Ciccullo, A., Borghi, V., Rusconi, S., Saracino, A., et al. (2023). Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype. VIRUSES, 15(3), 762 [10.3390/v15030762]. - dettaglio
Saladini, F., Giammarino, F., Maggiolo, F., Ferrara, M., Cenderello, G., Celesia, B.M., et al. (2023). Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 61(3), 1-8 [10.1016/j.ijantimicag.2023.106737]. - dettaglio
Rhee, S., Schapiro, J.M., Saladini, F., Zazzi, M., Khoo, S., Shafer, R.W. (2023). Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance. AIDS RESEARCH AND THERAPY, 20(1), 1-7 [10.1186/s12981-023-00503-5]. - dettaglio